Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Long-term effectiveness of dual CFTR modulator treatment of cystic fibrosis

Danya Muilwijk, Domenique D. Zomer-van Ommen, Vincent A.M. Gulmans, Marinus J.C. Eijkemans, Cornelis K. van der Ent, Dutch Cystic Fibrosis Registry (NCFR) Steering Group: , J. Altenburg, S.W.J. Terheggen-Lagro, H.G.M. Heijerman, K.M. de Winter-de Groot, M. Bakker, R.A.S. Hoek, H.M. Janssens, R. van der Meer, M. Nuijsink, H. van der Vaart, G.H. Koppelman, L.H. Conemans, M.A.G.E. Bannier, J.J. Noordhoek
ERJ Open Research 2022 8: 00204-2022; DOI: 10.1183/23120541.00204-2022
Danya Muilwijk
1Department of Pediatric Pulmonology, University Medical Center Utrecht, loc. Wilhelmina Children's Hospital, Utrecht, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Domenique D. Zomer-van Ommen
2Dutch Cystic Fibrosis Foundation (NCFS), Baarn, The Netherlands
4On behalf of the Dutch CF Registry Steering Group
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent A.M. Gulmans
2Dutch Cystic Fibrosis Foundation (NCFS), Baarn, The Netherlands
4On behalf of the Dutch CF Registry Steering Group
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marinus J.C. Eijkemans
3Department of Data Science and Biostatistics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cornelis K. van der Ent
1Department of Pediatric Pulmonology, University Medical Center Utrecht, loc. Wilhelmina Children's Hospital, Utrecht, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: k.vanderEnt@umcutrecht.nl
J. Altenburg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S.W.J. Terheggen-Lagro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H.G.M. Heijerman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K.M. de Winter-de Groot
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Bakker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R.A.S. Hoek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H.M. Janssens
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. van der Meer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Nuijsink
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. van der Vaart
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G.H. Koppelman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L.H. Conemans
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M.A.G.E. Bannier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.J. Noordhoek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Tables
  • Supplementary Materials
  • FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1

    Longitudinal time trends of clinical outcomes before and after cystic fibrosis transmembrane conductance regulator (CFTR) modulator initiation. Estimated longitudinal trends of per cent predicted forced expiratory volume in 1 s (FEV1 % pred), body mass index (BMI), BMI Z-score and annual intravenous (i.v.) antibiotic treatment duration. Time ranges from −7 years before to +3 years after CFTR modulator initiation, with time=0 (baseline) defined by the start date of CFTR modulator treatment. Dashed lines represent 95% confidence intervals, which are also given in parentheses. a) Mean FEV1 decline before CFTR modulator treatment was −1.36% pred per year (95% CI: −1.55– −1.17%), which changed by 0.88% pred per year (95% CI: 0.35–1.39%, p=0.001) after CFTR modulator initiation (table 2). The calculated FEV1 decline after modulator initiation (−0.48% pred per year, 95% CI: −0.99–0.01%) was added to the figure to illustrate the difference in FEV1 decline before and after CFTR modulator initiation. b) In adults ≥19 years, BMI gradually increased over time by 0.08 kg·m−2 per year (95% CI: 0.04–0.12 kg·m−2) before CFTR modulator treatment. This annual BMI trend did not significantly change (change: 0.10 kg·m−2 per year (95% CI: −0.01–0.21 kg·m−2, p=0.079)) in the years after modulator initiation (table 3). The calculated BMI after modulator initiation (0.18 kg·m−2 per year, 95% CI: 0.07–0.29 kg·m−2) was added to the figure to illustrate the difference in BMI before and after CFTR modulator initiation. c) In children <19 years, BMI Z-score initially decreased over time before CFTR modulator initiation, by a mean of −0.08 per year (95% CI: −0.10– −0.05). This annual trend significantly changed into an increasing trend (change: 0.14 per year (95% CI: 0.06–0.22, p<0.001)) in the years after CFTR modulator initiation (table 4). The calculated BMI Z-score after modulator initiation (0.06 per year, 95% CI: 0.03–0.14) was added to the figure to illustrate the difference in BMI Z-score before and after CFTR modulator initiation. d) The mean annual duration of i.v. antibiotic treatment (in days) increased by 16% (IRR: 1.16, 95% CI: 1.07–1.26, p<0.001) in the years preceding CFTR modulator treatment. In the year of CFTR modulator initiation, a drop in the mean duration of i.v. antibiotics was observed, leading to a three-times lower (IRR 0.28, 95% CI: 0.19–0.40, p<0.001) duration of i.v. antibiotic treatment compared to the years before CFTR modulator initiation. In the years after CFTR modulator initiation, the mean annual duration of i.v. treatment did not significantly change (change in IRR: 1.19, 95% CI: 0.94–1.50, p=0.153; table 5). The calculated IRR after modulator initiation (IRR: 1.84, 95% CI: 1.10–1.72) was added to the figure to illustrate the trend after CFTR modulator initiation.

Tables

  • Figures
  • Supplementary Materials
  • TABLE 1

    Baseline characteristics (n=401)

    CFTR modulator treatment, n (%)
     Lumacaftor/ivacaftor (LUM/IVA)401 (100)
     Transition to tezacaftor/ivacaftor (TEZ/IVA)208 (51.9)
     Time (years) to transition from LUM/IVA to TEZ/IVA, mean±sd2.0±0.6
    Death, n (%)2 (0.5)
    Lung transplantation, n (%)11 (2.7)
    Sex, n (%)
     Male233 (58.1)
     Female168 (41.9)
    Age (years), median (IQR)24.5 (18.0–31.5)
    Age 12–18 years, n (%)116 (28.9)
    Age >18 years, n (%)285 (71.1)
    Missing, n (%)0
    FEV1 % pred, mean±sd70.5±23.4
    FEV1 <40% pred, n (%)51 (12.7)
    FEV1 40–70% pred, n (%)128 (31.9)
    FEV1 70–90% pred, n (%)129 (32.2)
    FEV1 ≥90% pred, n (%)90 (22.4)
    Missing, n (%)3 (0.8)
    BMI adults (kg·m−2) ≥19 years, mean±sd21.4±2.5
     Missing, n (%)5 (1.8)
    BMI Z-score children 12–19 years, mean±sd−0.5±0.8
     Missing, n (%)0
    Received intravenous antibiotic treatment, n (%)
     Yes149 (37.3)
     No201 (50.0)
     Missing51 (12.7)
    Duration of intravenous antibiotic treatments in days, median (IQR)23 (17–42)
    Pseudomonas aeruginosa sputum culture status, n (%)
     Positive179 (44.6)
     Negative209 52.2)
     Missing13 (3.2)
    Staphylococcus aureus sputum culture status, n (%)
     Positive196 (48.9)
     Negative192 (47.9)
     Missing13 (3.2)
    Cystic fibrosis-related diabetes, n (%)
     Yes156 (38.9)
     No234 (58.4)
     Missing11 (2.7)
    Cystic fibrosis-related liver disease, n (%)
     Yes89 (22.2)
     No255 (63.6)
     Missing57 (14.2)

    Definitions: age was calculated at the date of CFTR modulator initiation (baseline). FEV1 % pred, BMI, BMI Z-score, number and duration of received intravenous antibiotic treatment, Pseudomonas aeruginosa and Staphylococcus aureus sputum culture status, CF-related diabetes and CF-related liver disease status reported at the last annual measurement preceding CFTR modulator initiation. The median duration of intravenous treatments was calculated for the 149 participants who received intravenous antibiotics in the last year prior to CFTR modulator initiation. BMI: body mass index. CFTR: cystic fibrosis transmembrane conductance regulator; FEV1 % pred: % predicted forced expiratory volume in 1 s; IQR: interquartile range.

    • TABLE 2

      Bayesian linear mixed effects model estimates of per cent predicted forced expiratory volume in 1 s (FEV1 % pred) (n=401, years of observation=3844)

      Unadjusted coefficient95% CIp-valueAdjusted coefficient#95% CIp-value
      Intercept69.0966.78–71.39<0.00170.9768.52–73.42<0.001
      Time−1.35−1.54 – −1.15<0.001*−1.36−1.55 – −1.17<0.001*
      CFTR modulator1.510.49–2.480.002*1.510.56–2.460.002*
      Time : CFTR modulator0.860.31–1.410.002*0.880.35–1.390.001*

      Interpretation: the intercept represents the mean FEV1 % pred of the study population at the time of CFTR modulator initiation (baseline). The coefficient of time (in years) reflects the mean annual FEV1 % pred decline in the years before CFTR modulator initiation. The coefficient CFTR modulator indicates the acute change in mean FEV1 % pred after CFTR modulator initiation, whereas time : CFTR modulator represents the change in annual FEV1 % pred decline in the years after CFTR modulator initiation compared to the years before. CFTR: cystic fibrosis transmembrane conductance regulator. #: coefficients were adjusted for the main effects of sex, age at baseline and the interaction effect of age at baseline with time; *: significance level p<0.05.

      • TABLE 3

        Bayesian linear mixed effects model estimates of body mass index (BMI) in adults ≥19 years (n=312, years of observation=2317)

        Unadjusted coefficient95% CIp-valueAdjusted coefficient#95% CIp-value
        Intercept21.4021.12–21.67<0.00121.3721.00–21.74<0.001
        Time0.060.03–0.31<0.001*0.080.04–0.12<0.001*
        CFTR modulator0.14−0.02–0.310.0860.14−0.03–0.310.097
        Time : CFTR modulator0.06−0.03–0.150.2170.10−0.01–0.210.079

        Interpretation: the intercept represents the mean BMI at the time of CFTR modulator initiation (baseline) in adults of 19 years and older. The coefficient of time indicates the mean annual change in BMI in the years before modulator initiation. The coefficient of CFTR modulator reflects the acute change in BMI after modulator initiation, whereas time : CFTR modulator represents the change in annual BMI in the years after CFTR modulator initiation compared to the years before. CFTR: cystic fibrosis transmembrane conductance regulator. #: coefficients were adjusted for the main effects of sex, age at baseline, the interaction effect of age at baseline with time and the interaction effect of age at baseline with time and CFTR modulator treatment; *: significance level p<0.05.

        • TABLE 4

          Bayesian linear mixed effects model estimates of BMI Z-score in children <19 years (n=225, years of observation=1552)

          Unadjusted coefficient95% CIp-valueAdjusted coefficient#95% CIp-value
          Intercept−0.60−0.73 – −0.47<0.001−0.85−1.08 – −0.62<0.001
          Time−0.06−0.09 – −0.05<0.001*−0.08−0.11 – −0.05<0.001*
          CFTR modulator0.003−0.15–0.150.9590.05−0.10–0.190.537
          Time : CFTR modulator0.130.05–0.210.002*0.140.06–0.22<0.001*

          Interpretation: the intercept represents the mean BMI Z-score at the time of CFTR modulator initiation (baseline) in children under 19 years (according to World Health Organization growth reference standards). The coefficient of time indicates the mean annual change in BMI Z-score in the years before modulator initiation. The coefficient of CFTR modulator reflects the acute change in BMI Z-score after modulator initiation, whereas time : CFTR modulator represents the change in annual BMI Z-score in the years after CFTR modulator initiation compared to the years before. BMI: body mass index. CFTR: cystic fibrosis transmembrane conductance regulator. #: coefficients were adjusted for the main effects of sex, age at baseline, the interaction effect of sex with time and the interaction effect of age at baseline with time; *: significance level p<0.05.

          • TABLE 5

            Negative binomial mixed effects model estimates of the duration of intravenous (i.v.) antibiotic treatment (n=364, years of observation=2805)

            Unadjusted coefficientIRR95% CI (IRR)p-valueAdjusted coefficient#IRR95% CI (IRR)p-value
            Intercept1.765.833.97–8.56<0.0011.484.382.82–6.79<0.001
            Time0.151.161.07–1.26<0.001*0.151.161.07–1.26<0.001*
            CFTR modulator−1.280.280.19–0.40<0.001*−1.280.280.19–0.40<0.001*
            Time : CFTR modulator0.161.180.93–1.490.1700.171.190.94–1.500.153

            Interpretation: coefficients are on the log-scale. Incidence rate ratios (IRRs) are transformed back to the original scale. The IRR of the intercept represents the mean duration of received i.v. antibiotics (in days) of the study population at the time of CFTR modulator initiation (baseline). The IRR of time shows the relative annual change in the duration of i.v. antibiotics before CFTR modulator treatment. The IRR of CFTR modulator reflects the acute change in the duration of i.v. antibiotics in the first year after CFTR modulator initiation, whereas time : CFTR modulator treatment indicates the relative change of i.v. antibiotic treatment in the years after modulator initiation compared to the annual trend before CFTR modulator use. CFTR: cystic fibrosis transmembrane conductance regulator. #: coefficients and IRRs were adjusted for sex and age at baseline; *: significance level p<0.05.

            Supplementary Materials

            • Figures
            • Tables
            • Supplementary Material

              Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

              Supplementary material 00204-2022.SUPPLEMENT

              Supplementary tables and figure legends 00204-2022.SUPPLEMENTARY_TABLES

              FIGURE S1 Comparison of longitudinal ppFEV1 trends before and after CFTR modulator initiation in subgroups with baseline ppFEV1 <40%, between 40-90% and ≥90%. 00204-2022.FIGURES1

              FIGURE S2 Comparison of longitudinal BMI and BMI Z-score trends before and after CFTR modulator initiation in subgroup with baseline ppFEV1 between 40-90%. 00204-2022.FIGURES2

              FIGURE S3 Comparison of longitudinal trends in IV antibiotic treatment duration before and after CFTR modulator initiation in subgroups with baseline ppFEV1 <40%, between 40-90% and ≥90%. 00204-2022.FIGURES3

            PreviousNext
            Back to top
            Vol 8 Issue 4 Table of Contents
            ERJ Open Research: 8 (4)
            • Table of Contents
            • Index by author
            Email

            Thank you for your interest in spreading the word on European Respiratory Society .

            NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

            Enter multiple addresses on separate lines or separate them with commas.
            Long-term effectiveness of dual CFTR modulator treatment of cystic fibrosis
            (Your Name) has sent you a message from European Respiratory Society
            (Your Name) thought you would like to see the European Respiratory Society web site.
            CAPTCHA
            This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
            Print
            Citation Tools
            Long-term effectiveness of dual CFTR modulator treatment of cystic fibrosis
            Danya Muilwijk, Domenique D. Zomer-van Ommen, Vincent A.M. Gulmans, Marinus J.C. Eijkemans, Cornelis K. van der Ent, Dutch Cystic Fibrosis Registry (NCFR) Steering Group: , J. Altenburg, S.W.J. Terheggen-Lagro, H.G.M. Heijerman, K.M. de Winter-de Groot, M. Bakker, R.A.S. Hoek, H.M. Janssens, R. van der Meer, M. Nuijsink, H. van der Vaart, G.H. Koppelman, L.H. Conemans, M.A.G.E. Bannier, J.J. Noordhoek
            ERJ Open Research Oct 2022, 8 (4) 00204-2022; DOI: 10.1183/23120541.00204-2022

            Citation Manager Formats

            • BibTeX
            • Bookends
            • EasyBib
            • EndNote (tagged)
            • EndNote 8 (xml)
            • Medlars
            • Mendeley
            • Papers
            • RefWorks Tagged
            • Ref Manager
            • RIS
            • Zotero
            Share
            Long-term effectiveness of dual CFTR modulator treatment of cystic fibrosis
            Danya Muilwijk, Domenique D. Zomer-van Ommen, Vincent A.M. Gulmans, Marinus J.C. Eijkemans, Cornelis K. van der Ent, Dutch Cystic Fibrosis Registry (NCFR) Steering Group: , J. Altenburg, S.W.J. Terheggen-Lagro, H.G.M. Heijerman, K.M. de Winter-de Groot, M. Bakker, R.A.S. Hoek, H.M. Janssens, R. van der Meer, M. Nuijsink, H. van der Vaart, G.H. Koppelman, L.H. Conemans, M.A.G.E. Bannier, J.J. Noordhoek
            ERJ Open Research Oct 2022, 8 (4) 00204-2022; DOI: 10.1183/23120541.00204-2022
            del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
            Full Text (PDF)

            Jump To

            • Article
              • Abstract
              • Abstract
              • Introduction
              • Materials and methods
              • Results
              • Discussion
              • Supplementary material
              • Acknowledgements
              • Footnotes
              • References
            • Figures & Data
            • Info & Metrics
            • PDF

            Subjects

            • CF and non-CF bronchiectasis
            • Pulmonary pharmacology and therapeutics
            • Tweet Widget
            • Facebook Like
            • Google Plus One

            More in this TOC Section

            Original research articles

            • Functional assay in CF organoids allows drug repurposing
            • Bacterial DNA amplifies neutrophilic inflammation in IL-17-exposed airways
            • PERSPIRE: a cohort study
            Show more Original research articles

            Cystic fibrosis

            • Functional assay in CF organoids allows drug repurposing
            • Nasal epithelial cell FRAP predicts CF therapy response
            • Diagnostic agreement in cystic fibrosis
            Show more Cystic fibrosis

            Related Articles

            Navigate

            • Home
            • Current issue
            • Archive

            About ERJ Open Research

            • Editorial board
            • Journal information
            • Press
            • Permissions and reprints
            • Advertising

            The European Respiratory Society

            • Society home
            • myERS
            • Privacy policy
            • Accessibility

            ERS publications

            • European Respiratory Journal
            • ERJ Open Research
            • European Respiratory Review
            • Breathe
            • ERS books online
            • ERS Bookshop

            Help

            • Feedback

            For authors

            • Instructions for authors
            • Publication ethics and malpractice
            • Submit a manuscript

            For readers

            • Alerts
            • Subjects
            • RSS

            Subscriptions

            • Accessing the ERS publications

            Contact us

            European Respiratory Society
            442 Glossop Road
            Sheffield S10 2PX
            United Kingdom
            Tel: +44 114 2672860
            Email: journals@ersnet.org

            ISSN

            Online ISSN: 2312-0541

            Copyright © 2023 by the European Respiratory Society